secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001628280-26-001273
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA rejects Vanda's HETLIOZ sNDA for jet lag disorder after expedited re-review
-------------------------------------------------------------------------------

- FDA concluded sNDA cannot be approved in current form, citing phase advance protocols not sufficiently analogous to actual jet travel.
- FDA acknowledged positive efficacy from controlled trials but said data do not provide substantial evidence of effectiveness.
- Vanda respectfully disagrees and will pursue all appropriate avenues for approval; notes prior D.C. Circuit ruling set aside FDA refusal.
- Expedited re-review was completed by Jan 7, 2026 under collaborative framework agreement from October 2025.
- HETLIOZ (tasimelteon) currently approved for non-24-hour sleep-wake disorder; jet lag would be new indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026001273/0001628280-26-001273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026001273/vnda-20260107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-001273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer